MYC and cancer: We have developed an injectable TME-responsive nanocomposite hydrogel loaded with an effective MYC inhibitor NHWD-870 and IL11Ra-targeted liposomes containing cisplatin-loaded MnO2, establishing a targeted chemotherapy-chemodynamic therapy-immunotherapy triple-combination therapy to restrain cancer growth.